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Review: Intensive Care

Antimicrobial Chemotherapy in the Intensive Care Unit
Louis D. Saravolatz, MD*

A

ntimicrobial chemotherapy represents a major tool for the
intensivist in rescuing the critically ill patient. Becau.se nosocomial infection is a frequent medical complication, affiicting
12.4% to 50% of patients, it behooves the intensive care specialist to utilize antimicrobial agents judiciously and effectively ( I ,
2). Nowhere in the hospital is the clinician's knowledge of drug
therapy more challenged than in the intensive care unit. Patients
present alterations in pharmacokinetics due to changes in drug
absorption, distribution, metabolism, and excretion. Further
confounding the treatment of intensive care unit infectious diseases is the occurrence of both unusual and resistant organisms
requiring the determination of whether to use newer agents or
older agents which may be effective for a new indication. Still
another clinical dilemma is recognizing adverse effects attributable to antimicrobial chemotherapy in a patient receiving multiple classes of drugs and who has multiple pathophysiologic
processes that have signs and symptoms similar to drug side effects. This article reviews antimicrobial agents utilized in the intensive care unit in relation to their mechanism of action, in vitro
activity, efficacy, pharmacokinetics, and adverse effects.

Aminoglycosides
Aminoglycosides have been available since the isolation of
streptomycin in 1944 (3). Although still used in the treatment of
mycobacteria, plague, brucellosis, and tularemia and as part of
the combination therapy in streptococcal endocarditis, streptomycin is rarely u.sed in the intensive care setting. The major aminoglycosides utilized include gentamicin. tobramycin, and amikacin. These drugs are presently needed to treat the most serious
intensive care unil gram-negative infections, except meningitis
and urinary tract infection. In addition, aminoglycosides have
some role in combination therapy of gram-positive infections.

into the growing peptide chains and faulty bacterial proteins are
produced.
Spectrum of in vitro activity

Aminoglycosides are active primarily against aerobic gramnegative bacilli. Staphylococcus aureus and Staphylococcus epidermidis. Of note is the absence of activity of aminoglycosides
against bacteria in anaerobic conditions. Thus, aminoglycosides
are inactive against anaerobes or conditions in which bacteria
have a low electrical potential, such as in abscesses (4). Additionally. Listeria monocytogenes and streptococci, including
Streptococcus pneumoniae, are generally resistant to clinically
achievable serum concentrations of aminoglycosides.
Table 1 provides the activity of gentamicin, tobramycin, and
amikacin against a large number of gram-negative bacilli. The activity of gentamicin parallels that of tobramycin, except in P.seudomonas aeruginosa where tobramycin demonstrates greater
activity than gentamicin, and in Serratia marcescens where gentamicin is more active lhan tobramycin. These results are similar
to those of most surveys done throughout the United States.
However, a difference noted in some areas, including our institution, has been the enhanced susceptibility of Acinetobacter
calcoaceticus var. anitratus. where tobramycin usually has
greater activity than gentamicin (5). Also, amikacin possesses
as much or more activity against all strains of bacteria tested.
Pharmacokinetics

Aminoglycosides are not absorbed when given orally and thus
are used as bowel preparations to suppress bacterial fiora ofthe
gastrointestinal tract prior to surgery or in cancer patients who
are placed in controlled environments such as laminar fiow
units. The drug may be given via intramuscular or intravenous
routes. The latter is preferred in order to achieve higher peak
serum concentrations. Peak serum concentrations are usually

Mechanism of action

The aminoglycosides are bactericidal agents that interfere
with protein synthesis. These agenls bind to the 30S subunit of
bacterialribosomes.The consequence ofthis binding is the misreading of the genetic code of DNA onto the messenger RNA
(transcription); thus, the wrong amino acids are incorporated
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Table t
Aminoglycoside Susceptibility of Gram-negative Bacilli*
% Susceptible

Organism
Acinelobaclcr calcoaceticus
Citrohacler freundii
Escherichia ctili
Enlerithuclcr acragenes
Enlerohacter cloacae
Klehsiella pneuniimiae
Proteus mirahilis
Pseudimionas aeruginosa
Serratia marcescens

No, of Strains
320
156
6,083
203
483
1,122
774
1,837
195

Gentamicin
43
81
'),S
9.-^
88

Tobramycin

Amikacin

53

90

79
99
94

IIKl

87

93
93

93
94

71
90

84
65

99
98
99

98
98
9.4
')7

*Dala collected in 1990 in collaboration wilh E. Mezger, MD, Director, Microbiology Laboralory, Henry
Ford Hospilal.

achieved I hour after an intramuscular dose and 30 minutes after
an intravenous infusion. Desired peak concentrations are generally 4 to 10 pg/mL for gentamicin and tobramycin and 25 to 35
pg/mL for amikacin. A predose (trough) concentration for aminoglycosides should be < 2 pg/mL for gentamicin and tobramycin and < 8 pg/mL for amikacin. The peak concentration has
been suggested as a predictor of clinical outcome, andthe trough
levels correlate best with toxicity. In the healthy adult with normal renal function, the half-life is 1.5 to 3.5 hours. The most frequent conditions requiring alterations of aminoglycoside dosages include the extremes of age as well as kidney disease; however, other conditions such as obesity, protein-calorie malnutrition, fever, and severe bums may significantly alter aminoglycoside levels and warrant careful monitoring of serum concentrations. In patients with normal renal function, a loading dose
of 1.5 to 2 mg/kg for gentamicin or tobramycin and 7.5 to 8 mg/
kg for amikacin will give the desired peak levels. The loading
dose should be the same regardless of the degree of renal dysfunction. After the loading dose, the maintenance dose in patients with normal renal function is usually 1.5 to 2 mg/kg every
8 hours for gentamicin and tobramycin and 7.5 mg/kg every 12
hours for amikacin. In the case of renal dysfunction, the daily
dosage may be reduced by multiplying it by the ratio of the patient's creatinine clearance to the normal creatinine clearance.
For example, using the equation of Cockcroft and Gault (6),
Cj.| (mL/min) = (140- age) x weight (kg) (x 0.85 for females)
Crx72
for a 40-year-old man with a weight of 70 kg and a serum creatinine of 5 mg/dL, the C^,, would be 20 mL/min and the normal
C|,| should be 100 mL/min. Thus, the daily maintenance dose
would be 20 mL/min divided by 100 mL/min x 4.5 to 6 mg/kg/
day = 0.9 to 1.2 mg/kg/day. This dose could then be given in one
of two ways; reduce the dose and maintain the same interval or
give the dose at less frequent intervals. There is no evidence to
support better efficacy with either approach; however, dose intervals should be reasonably convenient for nursing administra-
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tion. Despite extensive experience and even modifications of
nomograms, discrepancies may arise between desired and actual serum levels. Thus, frequent, carefully timed determinations are needed to assure adequate aminoglycoside levels in the
critically ill patient with gram-negative sepsis.
Aminoglycosides do not penetrate all body sites equally. They
do not achieve sufficient cerebrospinal fiuid penetration in adults
to cure patients even with infiamed meninges. Thus, these drugs
have been replaced in the treatment of gram-negative meningitis
by the third-generation cephalosporins.
Bronchial secretions are another important body site for penetration in the critically ill patient. Although studies have yielded
variable results, concentrations in bronchial secretions are approximately 20% of mean plasma levels (7). Furthermore, the low
pH of bronchial secretions may render aininoglycosides less active. Thus, when an aminoglycoside is used in gram-negative
pneumonia, a second drug is essential to achieve sufficient bactericidal activity. Aminoglycosides are eliminated unchanged
by the kidneys; therefore, hepatic insufficiency does not necessitate alteration in aminoglycoside dosing unless concomitant
renal dysfunction is present.
Efficacy in the intensive care unit
Despite the proliferation of newer and more active antimicrobial agents including the new beta-lactams, aminoglycosides are
still considered the mainstay of therapy in gram-negative sepsis.
These agents are almost always combined with beta-lactam antibiotics because of the additive or synergistic effect. In a study of
over 400 episodes of bacteremia due to gram-negative bacilli,
Anderson et al (8) showed that synergistic combinations of antibiotics had significantly higher response rates in seriously ill
patients with rapidly or ultimately fatal disease, shock, or neutropenia compared to patients who received two nonsynergistic
drugs. Aminoglycosides are considered interchangeable in terms
of efficacy; however, in infection caused by Pseudomonas aeruginosa, tobramycin is preferred over gentamicin because of
greater inhibitory activity. This may be significant in the intensive care unit, where Pseudomonas aeruginosa is the leading
cause of hospital-acquired pneumonia (9). As resistance rates to
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gentamicin and tobramycin increase, amikacin may be used to
treat specific infections. However, with increased usage, amikacin resistance will also occur. In an effort to preserve the effectiveness of amikacin, many infectious dLsease specialists recommend restricting use ofthis agent.
Adverse effects
Ototoxicity has been reported with comparable frequency for
all three aminoglycosides. Vestibular damage is more often associated with gentamicin and tobramycin, and cochlear damage
with amikacin. Ototoxicity may be increased by preexisting renal impairmeni. prior therapy wilh ototoxic drugs, therapy for
more than 10 days, high serum aminoglycoside levels, and concomitant administration of ethacrynic acid, furosemide, mannitol, and possibly other diuretics. If patients will receive aminoglycoside therapy for longer than three weeks, as in the case of
endocarditis or osteomyelitis, consideration should be given to
monitoring ototoxicity with vestibular or audiometric testing.
However, the ambience of the intensive care unit is not conducive to the performance of either ofthese tests.
Nephrotoxicity is the major toxicity of aminoglycosides, occurring in 2% to 10% of patients (10,11). Nephrotoxicity occurs
in the kind of patient frequently hospitalized in intensive care
units, specifically those who are debilitated, elderly, have contracted intravascular volumes, or have previous renal dysfunction. The studies published to date suggest that tobramycin is
less nephrotoxic than gentamicin. Since aminoglycoside nephrotoxicity is at least partially reversible, studies have concluded
that the lower nephrotoxic potential must be weighed against the
significant cost differential of these compounds. Thus, in patients with preexisting renal impairment, it may be prudent to
use tobramycin. In monitoring nephrotoxicity, the serum creatinine is an insensitive parameter. Therefore, monitoring urinary
cast excretion, which will increase before the serum creatinine,
is a much more .sensitive predictor of aminoglycoside-induced
nephrotoxicity.
Neuromuscular blockade is of concem in the critical care setting. The result of this may be fiaccid paralysis, respiratory depression, and dilated pupils. Aminoglycosides may act at two
different sites in causing this blockade (12). Though neuromuscular blockade is considered a rare event, it may be enhanced by
conditions that are sometimes not uncommon to the intensive
care unit, such as severe hypocalcemia, neuromuscular disease,
magnesium administration, botulism, ether anesthesia, d-tubocurarine, succinylcholine, and gallamine triethiodide (13,14).
The neuromuscular blockade has been associated with most
routes of administration and is related to the presence of high
concentrations of the drug at the neuromuscular junctions. Thus,
rapid bolus intravenous infusion or instillation of highly concentrated solutions into the pleural or peritoneal space will enhance the likelihood of achieving such high concentrations.
Treatment of the neuromuscular blockade should include avoidance of clinical situations that lead to high aminoglycoside concentrations, adminislralion of 0.25 mg neostigmine intravenously every 30 minutes until respiratory paralysis is reversed,
or the intravenous administration of 5.0 g of calcium gluconate
(15,16). Although both calcium gluconate and neostigmine
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have been found to be effective in reversing aminoglycoside-induced apnea, calcium gluconate is preferred since the benefit of
neostigmme has been variable. Also, repeated doses of calcium
and continued ventilatory support may be necessary in reversing
the neuromuscular blockade.
Other reactions that have been reported include eosinophilia.
rash, fever, leukopenia, and transient elevation of liver enzymes
(17). These reactions are rare and seldom serious.

Cephalosporins
The cephalosporin family of drugs represents the group of
antimicrobial agents with the largest number of new additions.
These drugs are compounds that are widely prescribed throughout the hospital, including the intensive care units. The number
of available agents has increased because they are safe and effective.
Mechanism of action
Cephalosporins are bactericidal drugs that act by binding to
penicillin-binding proteins (PBPs) that are associated with the
cell membrane of bacterial cells (18). The PBPs are enzymes,
endopeptidases, transglycosylases, transpeptidases, and carboxypeptidases that are necessary for the biosynthesis of peptidoglycan, which is the backbone of bacterial cell walls. When
binding with the PBPs occurs, autolysins may be released resulting in cell death. If a bacterium is deficient in the autolysins.
then the growth may only be inhibited and the organism is referred to as tolerant to the antibiotic. Since at least seven different PBPs exist, there may be some rationale in combining betalactam drugs that act on different PBPs in order to achieve a synergistic effect. On the other hand, some beta-lactam agents may
be antagonistic when combined and thus synergy studies need
to be performed in order to identify appropriate combination
therapy (19).
Spectrum of In vitro activity
Cephalosporins have been classified in terms of "generations"
which are based on in vitro activity. Table 2 lists the available
agents in each of the generations. The first-generation agents
have good activity against gram-positive cocci, except Enterococcus faecalis. methicillin-resistant Staphylococcus aureus.
and Staphylococcus epidermidis. All generations of cephalosporins have good activity against Escherichia coll. Klebsiella
pneumoniae, and Proteus mirahilis. The second-generation
agents show only slightly greater activity against gram-negative
organisms susceptible to first-generation cephalosporins. However, a word of caution is needed about the greater gram-negative activity of cefamandole. Some organisms, especially Enterobacter species, emerge resistant to cefamandole after being
susceptible initially (20). This phenomenon is due to the derepression of chromosomally-mediated beta-lactamase. For this
reason, cefamandole should never be used as the sole agent in
the therapy of serious Enterobacter infections.
Due to the in vitro activity of the second-generation cephalosporins, these agents have two major advantages. First, all second-generation cephalosporins have a minimal inhibitory con-
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Table 2
Cephalosporins for Serious Infections
First
Generation
Cefazolin
(Ancef, Kefzol)
Cephapirin
(Cefadyl)
Cephalothin
(Keflin)
Cephradine
(Velosef, Anspor)
Cefadroxil
(Duricef. Ultracef)
Cephalexin
(Keflex)

Adult
Dose

Half-life
(M)

1 g/8 hr

1.5

2 g/4 hr

0,6

2 g/4 hr

0,6

2 g/4 hr

1,3

1 g/I2hr
(orally)
1 g/6 hr
(orally)

1,5
1,3

Second
Generation

Adult
Dose

Half-life
(M)

Cefamandole
(Mandol)
Cefonicid
(Monicid)
Ceforanide
(Precef)
Cefoxitin
(Mefoxin)
Cefuroxime
(Zinacef)
Cefaclor
(Ceclor)
Cefmetazole
(Ef'azone)

2 g/6 hr

0,8

2 g/24 hr

4,4

1 g/l2hr

3,0

2 g/6 hr

0,8

1,5 g/8 hr

1,5

1 g/8 hr
(orally)
2 g/8 hr

o,x
1,3

Third
Generation
Ceftizoxime
(Ceftizox)
Cefotaxime
(Claforan)
Ceftriaxone
(Rocephin)
Cefmenoxime
(Cefmax)
Cefotetan
(Cefotan)
Moxalactam
(Moxam)
Cefoperazone
(Cefobid)
Cefsulodin
(Cefomonil)
Ceftazidime
(Fortaz, Tazideme.
Tazicet)

Adult
Dose

Half-life
(M)

2 g/8 hr

1,7

2 g/6 hr

l.l

2 g/24 hr

8,0

2 g/6 hr

1.0

2g/l2hr

4.(1

2 g/8 hr

l.n

2 g/8 hr

1,9

2 g/8 hr

I.H

2 g/8 hr

4,4

Note: Cephalosporins are I sted hy generic names with proprietary names in pa ren the ses.

centration of 90% of isolates (MlCt,,,) of < 6.0 |J,g/mL for Haemophilus influenzae while first-generation cephalosporins have
a MlCy,, of 10 pg/mL. Additionally, second-generation cephalosporins appear to be resistant to the beta-lactamase that some
strains of Haemophilus influenzae produce. Another advantage
is that cefoxitin, one of the second-generation cephalosporins,
has excellent in vitro activity against Bacteroides fragilis. The
MICyo for cefoxitin is < 16 pg/mL, which makes it one of the
most active cephalosporins against Bacteroides fragilis. In
terms of gram-positive activity, the second-generation cephalosporins have less activity than the first-generation agents
against Staphylococcus aureus. Staphylococcus epidermidis.
Streptococcus pyogenes, and Streptococcus pneumoniae. The
third-generation cephalosporins demonstrate even greater activity against gram-negative organisms than either the first- or
second-generation cephalosporins against the enterobacteriaceae. Ceftizoxime, cefotaxime, ceftriaxone, moxalactam, and
ceftazidime have comparable activity against the enterobacteriaceae and are more active against these organisms than the other
available cephalosporins. Cefoperazone is next in orderof activity against the enterobacteriaceae and is more active than cefsulodin. The agents active against Pseudomonas aeruginosa, in
orderof activity, are ceftazidime, cefsulodin, cefoperazone, and
moxalactam. Susceptibility to Pseudomonas aeruginosa will
vary from ho.spital to hospital and even within hospitals from
ward to ward. Comparing reported susceptibilities of Pseudomtmas aeruginosa from unselected strains to susceptibilities
from isolates from Henry Ford Hospital intensive care unils
demonstrates that imipenem has the greatest in vitro activity followed by ceftazidime and then cefoperazone (19,21). Clearly,
the more resistant organisms exist in these units where antibiotic
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selective pressures are more intense. Despite the enhanced
gram-negative activity, the acfivity of the third-generation cephalosporins is considerably less than either first- or second-generation cephalosporins against gram-positive organisms such as
Staphylococcus aureus. Staphylococcus epidermidis. Streptococcus pneumoniae, and group B streptococci. In addition, organisms such as Listeria monocytogenes and Clostridium difficile are quite resistant to cephalosporins. In general, cephalosporins are usually active against peptococcus, peptostreptococcus, fusobacterium, and Clostridium (excluding Clostridium difficile). Most cephalo.sporins have poor activity against
Bacteroides fragilis and variable activily against other Bacteroides species. The cephalosporins with the greatest activity
against all anaerobes include cefoxitin, cefotetan, and ceftizoxime.
Pharmacokinetics
Cephalosporins may be given via oral, intramuscular, or intravenous routes. Table 2 gives the usual dose and half-life of
each agent. With doses listed in Table 2 for parenteral agents, serum concentrations may range from 60 to 270 |j,g/mL.
The.se drugs are excreted primarily by renal mechanisms, either glomerular filtration and/or tubular secretion. Serum concentrations of agents that are not excreted by tubular secretion
are not infiuenced by agents that block secretion, such as probenecid.
The cephalosporins generally have a significant prolonged
half-life in the face of renal failure. The two exceptions are cefoperazone and ceftriaxone, which are the only cephalosporins
whose half-life shows less than a twofold increase when the
creatinine clearance is less than 10 mL/min. These drugs have a
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dual route of excretion including an important hepatobiliary
route. In general, dose adjustments for cephalosporins are
needed in moderale to severe renal failure. The interval is prolonged to 1.5 to 2 times in moderate renal failure (creatinine
clearance = 10 to 15 mL/min) and 3 to 4 times in severe renal
failure (creatinine clearance < 10 mL/min). In the case of cefoperazone and ceftriaxone, no do.se adjustment is needed for renal failure.
Cephalo.sporins tend to penetrate most body sites well, including bone, biliary tree, and the respiratory tree. However,
cerebrospinal fluid activity varies with the intrinsic in vitro activity ofeach agent against the pathogens that cause meningitis.
Approximately 5% to 20% of the serum level can be achieved in
the cerebrospinal fluid when giving ceftizoxime. cefotaxime,
ceftriaxone, ceftazidime, cefsulodin, or moxalactam to patients
with inflamed meninges. These agents tend to be active against
the organisms that cause gram-negative bacillary (including
Haemophilus influenzae) meningitis. However, these agents are
not appropriate for Listeria monocytogenes or group B streptococcal meningitis. Also, penicillin remains the trealment of
choice for pneumococcal meningitis since failure has been observed with agents such as cefotaxime and moxalactam due to
the inability to achieve cerebrospinal fluid concentrations in excess ofthe MIC for some strains of Streptococcus pneumoniae.
Efficacy in the intensive care unit
Cephalosporins are an extremely popular group of antimicrobial agents in the intensive care unit as well as in the rest of the
hospital. Their safety and efficacy profile accounts for their extensive use. These agents may be used in monotherapy for urinary tract infections and for empiric therapy of mild to moderately severe soft tissue infections. In life-threatening infections,
especially pneumonias, combination therapy is preferred to increase spectrum, to achieve synergy, and to delay the emergence
of resistance. First-generation agents are frequentiy used in the
empiric therapy of community-acquired pneumonia or sepsis
when combined with an aminoglycoside. If an intraabdominal focus is strongly suspected, first-generation cephalosporins
would not be appropriate but clindamycin or metronidazole are
considered the antianaerobic agents with the greatest activity.
In intraabdominal or pelvic sepsis, cephalosporins such as cefoxitin, cefotetan, or ceftizoxime are preferred. The second-generation cephalo,sporins such as cefamandole and cefuroxine
have little role in the adult intensive care unit. They can be considered for infections such as sinusitis or orbital cellulitis where
pathogens such as Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus may be present as a mixed
infection. However, cefamandole does not penetrate the cerebrospinal fiuid well and should be avoided if there is a concern
of meningifis. The third-generation cephalosporins, especially
those with antipseudomonal activity, have an important role in
the intensive care unit, especially for empiric or definitive treatment ofthe more difficult infections with organisms such as Enterobacter. indole-positive Proteus, Serratia, or Pseudomonas
aeruginosa. These third-generation cephalosporins should also
be combined with aminoglycosides in most intensive care unit
settings. The only severe infection where monotherapy would
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be acceptable is in the case of gram-negative meningitis. Another area where monotherapy could be considered is in the case
of non-life-threatening sepsis where the concem of the nephrotoxicity associated with aminoglycoside therapy outweighs the
concern over the outcome ofthe sepsis.
Adverse effects
The cephalosporin class of antimicrobial agents are relatively
safe drugs. The incidence ofall adverse effects is between 5% to
10%. However, most of these reactions are not serious or lifethreatening. The most common reaction to the cephalosporins is
hypersensitivity, which includes rash, fever, serum sickness,
and immediate reactions.
A history of penicillin allergy frequently precludes the physician from administering a cephalosporin. This approach is not
entirely justified and requires some qualification. Immunologic
studies have shown cross-reactivity between patients with penicillin and cephalosporin allergy (22). Clinical data would suggest that the allergic reactions are not more frequent than 5%
(23). However, immediate severe reactions to cephalosporins
have occurred in at least three penicillin-allergic patients (24).
Thus, though the risk of administering cephalosporins to penicillin-allergic patients is small, it would be best to avoid the use
of these agents in patients with a history of anaphylaxis, bronchospasm, or urticaria after penicillin administration.
Cephalosporins have been considered as potentially nephrotoxic. However, this is true only with cephaloridine, which is no
longer in use in the United States, or when cephalosporins are
combined with aminoglycosides. By themselves, these agents
rarely cause acute tubular necrosis or a hypersensitivity interstitial nephritis.
Other side effects, which are common but usually not serious,
are gastrointestinal symptoms. These include diarrhea, nausea,
vomiting, abdominal pain, and flatulence. Additionally, Clostridium difficile-ansociatcd pseudomembranous enterocolitis,
though uncommon, has been reported with all of the cephalosporin antimicrobial agents. Liverenzyme elevation suggestive
of hepatocellular dysfunction may also occur in approximately
3% of patients. However, clinically significant liver dysfunction
secondary to cephalosporins has not been reported.
Another group of reactions has been related to the methylthiotetrazole (MTT) side chain of cephalosporins and includes
cefamandole, cefoperazone, moxalactam, cefotetan, cefmenoxime, and cefmetazole. The reactions related to this .structure include an alcohol-related disulfiram reaction as well as bleeding
diatheses related to hypoprothrombinemia. The hypoprothrombinemia can be avoided by using lower doses of the beta-lactam
containing the MTT side chain or by the concomitant administration of AquaMEPHYTON. Despite the presence ofthe MTT
side chain, a cephalosporin will vary in its ability to cause bleeding problems. Considerably more bleeding problems have been
identified with moxalactam whereas few cases have been reported with cefotetan. Other hematologic manifestations have
included immune thrombocytopenia, qualitative platelet defects, and Coombs-positive hemolytic anemias.
Olher side effects ofthe cephalosporins have included central
nervous system manifestation,s—vertigo, hallucinations, nys-
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tagmus, reversible encephalopathy, and seizures (14). These
side effects are more frequent ifthe patient has renal failure or if
the drug is given either in high doses or intrathecally.

Extended Spectrum Penicillins and
Other Related Antimicrobial Agents
Penicillin is an antimicrobial agent not commonly used in the
intensive care unit. However, through structural alterations of
penicillin, new compounds with improved antimicrobial properties and different pharmacologic parameters have been developed. As a group, the penicillin family has a significant role in
the treatment of seriously ill, hospitalized patients, especially
those in the intensive care unit.
Mechanism of action
The penicillins are generally bactericidal antimicrobial agents
which inhibit bacterial cell wall synthesis as described in the
section on cephalosporins. The site of action is the binding of
the beta-lactam to a PBP found in the plasma membrane fraction. The relative affinity for PBPs by various penicillins determines the microbiologic activity of these agents. The PBPs most
important in gram-positive bacteria include PBP-1, -2. and -4.
Thus, the new agents, amdinocillin and aztreonam, which do not
bind these PBPs of gram-positive bacteria, are not active against
these organisms. PBPs vary in their ability to bind beta-lactams
as well as in their catalytic activity for peptidoglycan formation.
Therefore PBPs vary in their killing potential against the bacteria and some lead only to the development of elongated or filamentous forms, whereas others lead to osmotically fragile

forms with subsequent lysis. The significance of structural alterations in predicting clinical response is not known. Thus, bacterial structural alteration cannot be used as a parameter for selecting specific antimicrobial agents. However, new agents, such as
amdinocillin and imipenem, which bind to PBP-2 of gram-negative organisms, may indicate an advantage ofthese compounds
since most penicillins do not bind to the PBP-2 of gram-negative bacteria.
Spectrum of in vitro activity
Table 3 summarizes the relative activity of the penicillins
(25.26). Penicillin demonstrates excellent activity against grampositive organisms but no activity against gram-negative enteric
organisms, penicillinase-producing gram-positive organisms, or
penicillinase-producing Haemophilus influenzae. Penicillin is
active against anaerobes except for Bacteroides fragilis and recent isolates of Bacteroides melaninogenicus. Ampicillin demonstrates similar activity to penicillin, except it is more active
against Enterococcus faecalis and Haemophilus influenzae and
demonstrates activity against gram-negative organisms such as
Escherichia coli and Proteus mirahilis. Nafcillin, a prototype
penicillinase-resistant penicillin, overcomes inactivity by the
beta-lactamase produced by Staphylococcus aureus. Of special
note is the poor antianaerobic activity of nafcillin. The extended
spectrum penicillins, azlocillin, mezlocillin, and piperacillin,
have greater activity against gram-negative organisms including Escherichia coli. Klebsiella pneumoniae, Proteus mirahilis,
Enterobacter, Serratia. and Pseudomonas aeruginosa. The addition of beta-lactamase inhibitors, clavulanic acid and sulbactam, enhances the activity of the penicillins against organisms

Table 3
Comparative In Vitro Activities of the Pencillins Against Aerobic and Anaerobic Organisms

Organism

Slreplitcoccus pneumoniae
Streptococcus jiyitgcnes
Sireplococcus ai>alacliac
SircpliKtKCUs viridans
EnlernctK cus faecalis
Siaphylococcus aureus:
Penicillinase (-)
Penicillinase (+)
yv ei sser la i>ont>rrhoeac
Neisseria meningitidis
Clostridium perfringens
Bacteroides fragilis
Bacteroides melaninogenicus
PeploslreploctKcus
Fusobacterium nucleatum
Escherichia coli
Klehsiella pneumtmiue
Proteus mirahilis
Enterohaclcr
Serratia
Pseudimiimas aeruginosa
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Table 4
Pharmacokinetic Considerations for Penicillins
Interval

Penicillins
Penicillin
Ampicillin
Nafcillin
Ticarcillin
Azlocillin
Mezlocillin
Piperacillin

Dosage
25,000-300.000 U/kg/day
100-200 mg/kg/day
100-200 mg/kg/day
ltX)-400 mg/kg/day
200-300 mg/kg/day
200-300 mg/kg/day
200-300 mg/kg/day

Normal
Renal Function
4hr
4hr
4hr
4hr
6hr
6hr
6hr

CC
(<10 mL/min)
6-8 hr
8hr
4hr
12 hr
8-l2hr
8-12 hr
8-l2hr

CC = creatinine clearance.

such as Staphylococcus aureus, Klehsiella pneumoniae, Bacteroides fragilis. and beta-lactamase-producing Haemophilus influenzae. This is the basis for the enhanced activity of combination agents such asticarcillin-clavulanicacid and ampicillinsulbactam.
Pharmacokinetics
Intensive care unit use ofthe penicillins is generally confined
to parenteral administration. Because of their short half-lives,
nafcillin, ampicillin, and ticarcillin are administered every 4
hours. The newer extended penicillins are administered less frequently (Table 4). Penicillins are excreted via renal tubular excretion which may be blocked by probenecid, with a prolongation of serum half-lives. It is unnecessary to reduce the dose of
penicillin unless there is a moderate degree of renal dysfunction
(creatinine clearance < 10 mL/min), except for nafcillin, only
30% of which is excreted into the urine, the remainder inactivated in the liver (27).
Penicillins are well distributed in most body areas including
the lung, kidney, bone, bile, pleura, peritoneum, and synovium.
In the presence of acute inflammation, penetration is sufficiently enhanced into the cerebrospinal fluid, brain, eye, and
prostate so that these agents are generally effective against susceptible organisms.
Intensive care unit needs
Penicillin or ampicillin is the treatment of choice in the intensive care unit for infecfion caused by Streptococcus pneumoniae. Staphylococcus pyogenes. Streptococcus agalactlae (group
B). Streptococcus viridans. Streptococcus bovis. Enterococcus
faecalis. Listeria monocytogenes. Neisseria meningitidis. Actinomyces, and Clostridium. The frequency of isolating beta-lactamase-producing Staphylococcus aureus. Haemophilus Influenzae, and Neisseria gonorrhoeae has necessitated identification of alternate agents. Staphylococcus aureus can best be
treated by a semisynthetic penicillin such as nafcillin, methicillin, or oxacillin. However, Staphylococcus aureus infecfions
in the intensive care unit are often mixed, as is the case with
pneumonia or wound infections. In such cases, another agent
with a greater spectrum as well as antistaphylococcal activity
may be preferred. Also, beta-lactam-resistant infections are fre-
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quent, especially at the larger referral hospitals, in bum units, or
intensive care units (28). As a result, vancomycin has become a
mainstay of antistaphylococcal therapy in some areas where the
frequency of beta-lactam-resislant Staphylococcus aureus justifies this approach. The occurrence of penicillinase-producing
Haemophilus influenzae is much less common in adults than in
children, so that empiric therapy against such strains for the
adult intensive care unit patient is not warranted at thistimeunless there is epidemiologic evidence to suggest that the problem
is frequent.
The main use of penicillin for the intensive care unit is with
the extended spectrum penicillins. Ticarcillin has been replaced
by mezlocillin, piperacillin, and azlocillin. These agents, when
combined with an aminoglycoside, often provide a synergistic
antibacterial combinalion againsi most aerobic gram-negative
bacilli responsible for nosocomial intensive care unit pneumonias. In addition, these agents have excellent activity against anaerobic and gram-positive organisms except for Siaphylococcus
aureus. Because of their excellent in vitro activity, the extended
spectrum penicillins, when combined wilh aminoglycosides,
can be used as empiric therapy for .sepsis of most sites in the critically ill patient, unless Staphylococcus aureus or gram-negative meningitis is suspected.
Adverse effects
The major side effects of the penicillins are hypersensitivity
reactions. Penicillin reactions ofthe immediate type are of great
concern. Anaphylaxis occurs in approximately four cases in
100.000 courses of penicillin administration and has been reported most frequentiy with penicillin (29). Delayed hypersensitivity reactions, including dermatitis, are more common with
ampicillin and may occur as often as 4% to 8%.
Penicillin reactions are due to penicillin derivatives attaching
to human proteins. The most important penicillin derivative is
produced by opening of the beta-lactam ring, resulting in the
penicilloyl derivative. Acid treatment of penicillin results in
penicillanic acid. Major determinants of penicillin allergy include penicilloyl and penicillanic acid. Minor determinants are
benzyl penicillin or sodium benzyl penicillin. Both major and
minor determinants are associated with IgE-mediated reactions
including urticaria, laryngeal edema, and anaphylaxis. Minor
determinants, however, are the main cause of anaphylactic reactions. If skin testing is performed with major and minor determinants and there is failure to react to these determinants, there is a
less than 5% chance ofan immediate reaction occurring (30).
Gastrointestinal side effects have also occurred commonly
with the penicillins, with ampicillin causing diarrhea in as many
as 25% of patients. Pseudomembranous enterocolitis has also
been reported with all ofthe penicillins.
Hematologic reactions may occur, including neutropenia and
Coombs-positive hemolytic anemia. In addition, penicillin may
bind to platelets resulting in a defect in platelet aggregation and
rarely clinical bleeding (31).
Interstitial nephritis has been associated with high-dose penicillin administration after one week of therapy. These patients
often have fever, rash, eosinophilia, albuminuria, and a rise in
serum creatinine. Melhicillin is the most likely penicillin to
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cause interstitial nephritis (32). This immunologic complication
is reversible after cessation of the penicillin, but it is inadvisable
to give another penicillin during this clinical complication.
Melhicillin also has been reported to cause hemorrhagic cystitis.
Neurotoxicity which may occur wilh penicillin includes coma
and seizures (33). This is most likely to occur in elderly patients
with renal failure, or with intrathecal administration ofthe drug.
Caulion is necessary when adjusting the dose under these conditions.
Severe hypokalemia may also be seen, with serum potassium
levels of less than 2 mEq/L. This is due to kaliuresis that occurs
when a large amounl of nonreabsorbable anion is delivered to
the distal tubule (34).
Carbapenems and monobactams
A new class of beta-lactams, termed "carbapenems," developed in recent years differ from cephalosporins and penicillins
in terms of antibacterial properties. Imipenem is a prototype of
the carbapenems. This agent has the greatest microbiologic activity ofany agent available today (35). It is active against streptococci and staphylococci wilh a MICy
.0 pg/mL. The enterobacteriaceae are generally susceptible to 1.0 pg/mL and
Pseudomonas aeruginosa is usually susceptible to imipenem.
However, Pseudomonas cepacia, Xanthomonas maltophllia.
and Enterococcusfaeclum are usually resistant. Most anaerobes
are sensitive to imipeneiTi with a MIC^o of 0.2 |ig/mL for Bacteroides fragilis. The use of imipenem has been effective in many
serious infections caused by susceptible organisms. Because the
use of imipenem alone in the treatment of Pseudomonas aeruginosa has been associated with the emergence of resistance,
aminoglycosides should be added lo the therapy if possible.
Imipenem has been used safely with only rare major adverse effects. Seizures have been observed as a side effect of imipenem
in seriously ill patients in the intensive care unit; however, this
may be no greater than the overall incidence of seizures in this
patient population. The dose of imipenem is 250 to 1,000 mg
every 6 hours. Dose adjustments should be made when renal insufficiency is presenl.
Azthreonam, a monobactam, is a monocyclic beta-lactam
which has excellent activily against gram-negative organisms.
This agent has the advantage of lower cross-reactivity with betalactams in patients with a history of hypersensitivity reaction to
penicillins and cephalosporins. Many Pseudomonas aeruginosa
are inhibited by 25 pg/mL; however, Xanthomonas maltophllia
and Pseudomonas cepacia are usually resistant (36). Additionally, monobactams do not have activity against anaerobes and
gram-positive bacteria. Usual doses of azthreonam are I to 2 g
every 8 hours.

Vancomycin and Teicoplanin
Use of vancomycin, a complex glycopeptide, has significantiy increased throughout hospitals and especially in intensive care units. The increased usage is due not only to the increasing importance of staphylococcal infections, including
both methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis. but also to its continued unnecessary use
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Table 5
Comparative In Vitro Susceptibility of Gram-positive Cocci
to Vancomycin and Teicoplanin
Vancomycin

Siaphylococcus aureus
Methicillin-resistant
Methicillin-sensitive
Siaphylococcus epidermidis
SlaphyltK tK cus saprophylicus

Teicoplanin

MIC,,,

MIG,,,

MIC,,,

MIG,,,

0,78
0,78
1,56
0,78

0,78
0,78
3,12
1,56

0,097
0,195
< 0,024
0,195

0,097
0,195
< 0,024
0,78

MIC = minimum inhihitorv concenlralion.

when a less expensive agent can be shown to be active against
the patient's pathogen.
Mechanism of action
Vancomycin binds to the cell wall of sensitive bacteria and
thus inhibits cell wall synthesis. This occurs by binding to peptide side chain ending in acyl-D-ala-D-ala ofthe mucopeptide in
the cell wall (37). Also, vancomycin inhibits the growth of spheroplasts by acling on the cytoplasmic membrane.
Spectrum of in vitro activity
Table 5 shows vancomycin's and teicoplanin's activity against
gram-positive organisms. In addition to these gram-positive organisms, vancomycin is also active against Streptococcus pneumoniae. Streptococcus pyogenes. Streptococcus agalactlae.
Streptococcus viridans. Listeria monocytogenes, Clostridia (including Clostridium difficile). Bacillus anthracis, Actinomyces,
lactobacilli, diphtheroids, and J-K bacillus. Although vancomycin is usually bactericidal for most gram-positive organisms,
Enterococcus faecalis is usually tolerant to the antibiotic andconcentrations in excess of 100 pg/mL are required to achieve a
bactericidal effect.
Pharmacokinetics
Vancomycin can be given orally or intravenously. The intramuscular route of administration is not well tolerated due to severe pain. Teicoplanin. however, can be given by this route and
is well tolerated. Vancomycin given orally yields undetectable
serum levels even in the presence of renal failure. However, in
the diseased gastrointestinal tract, such as in pseudomembranous colitis due to Clostridium difficile, serum concentrations as
high as 5 pg/mL may be detected (38). Thus, vancomycin's oral
administration is limited to patients with Clostridium difficile
colitis or as part of the antibacterial bowel suppression for cancer patients. When giving vancomycin intravenously, the infusion should be administered over 30 to 60 minutes to minimize
untoward effects such as flushing, syncope, and arrhythmia.
When I g of the drug is given intravenously, peak levels of 20 to
50 pg/mL and trough levels of 5 to 10 P-g/mL can be achieved.
Serum levels should be obtained one hour after a 60-minute infusion because of the three-stage distribution of the drug and the
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moderately variable serum results that occur in the hour after infusion.
Vancomycin achieves adequate levels in urine and pleural,
pericardial, synovial, and ascitic fluids. However, in the aqueous humor, bile, and cerebrospinal fluid, levels are generally
low. The level in cerebrospinal fluid tends lo be greater in the
presence of inflammation and in younger patients. Clinical data
on the treatment of meningitis with systemic vancomycin alone
have not been plentiful. Since the mean cerebrospinal fluid level
achieved in adults with meningitis is 2.5 pg/mL which barely
exceeds the MIC of the organism, some clinicians have chosen
to administer the drug by the intrathecal or intraventricular
route, via a reservoir (39).
Vancomycin has lirtle, if any, nonrenal metabolism. It is
cleared by glomerular filtration. However, a report of a patient
with only hepatic dysfunction demonstrated that a prolonged
half-life may occur and dose adjustments may be needed (40).
The usual dosing of vancomycin is 15 mg/kg every 12 hours for
adults. In the face of renal insufficiency, a daily parenteral dose
of 150 mg plus 15 times the creafinine clearance can be given
(41). Another approach is to give 1 g every 36 hours if the serum
creatinine concentration is 1.5 to 5.0 mg/dL and 1 gevery 7 to 14
days if the creatinine is > 5 mg/dL (42).
Efficacy in the intensive care unit
Vancomycin is commonly used in the intensive care unit in
the treatment of serious gram-positive infections. Vancomycin
is the treatment of choice for Staphylococcus aureus and Staphylococcus epidermidis infection in patients with beta-lactam
(melhicillin, nafcillin. oxacillin, or cephalosporin)-resistant organisms or a history of hypersensitivity to these drugs. Al Henry
Ford Hospital, as many as 50% of Staphylococcus epidermidis
cases may be resistant to the semisynthetic penicillins and require vancomycin for therapy. Since Staphylococcus epidermidis followed by Staphylococcus aureus are frequent pathogens in device-related sepsis, the following infections are frequentiy treated with vancomycin: catheter .sepsis, prosthetic
valve endocarditis, prosthetic joints, vascular grafts, dialysis access sites, and cerebrospinal fiuid shunts.
Vancomycin is also used in the treatment of enterococcal infecfions when the patient has a history of penicillin hypersensitivity or in the unusual case of penicillin resistance. If an endovascular infection is suspected, an aminoglycoside should be
added to achieve a bactericidal regimen.
Orally administered vancomycin is the treatment of choice
for pseudomembranous enterocolitis. A dose of 125 mg, four
times daily, has been effective
Teicoplanin, though used in limited amounis, has the advantage of once daily administration, as well as intramu.scular administration. Currently available data are insufficient lo delermine its efficacy in intensive care unit-related sepsis.
Adverse effects
Although perceived by many clinicians as a highly toxic compound, the current formulation of vancomycin is relatively safe
when given at a slow infusion rate. The most frequent adverse
effects will occur during or shortly after administration of the
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drug. A histamine release results in an erythematous flushing
("red man syndrome") accompanied by pruritus or hypotension.
Vancomycin should be infused over 45 lo 60 minuies. Should
the "red man syndrome" occur, treat with benadryl intravenously.
Nephrotoxicity, defined as a rise in .serum creatinine of 0.5
mg/dL, may occur in 5% of patients receiving vancomycin
alone (43). The addition of an aminoglycoside may be associated with a greater risk of nephrotoxicity than when either agent
is administered alone.
Vancomycin also may be ototoxic, with hearing impairment
rather than vestibular damage being the major toxicity. In general, renal insufficiency and/or excessive serum levels have
been the major risk factors for ototoxicity.
Neutropenia has also been reported with vancomycin. Drugas.sociated neutropenia usually occurs after several weeks of
therapy and is reversible over two to nine days after discontinuation of therapy. Other reported hematologic toxicities have included anemia and thrombocytopenia.
Olher reported side effects of vancomycin have included
phlebitis, drug fever, rash, anaphylactic reactions, and nausea.

Clindamycin, Metronidazole, and
Chloramphenicol
The antimicrobial agents discussed in this section have been
grouped together because of their excellent antianaerobic activity, especially against Bacteroides fragilis. Because of this activily, these agents are of considerable importance in the treatment of intraabdominal sepsis where Bacteroides fragilis is a
major pathogen.
Mechanism of action
Clindamycin and chloramphenicol act by attaching to the 50S
ribosomal binding sites and impairing protein synthesis. Metronidazole, on the other hand, is bactericidal by reductive activation to a compound that acts as a preferential electron acceptor
which results in production of short-lived intermediate compounds or free radicals that damage DNA (44).
Spectrum of in vitro activity
Clindamycin, metronidazole, and chloramphenicol all have
excellent activity against the anaerobes, especially Bacteroides
fragilis. Occasional strains of Bacteroides fragilis resistant to
clindamycin have been reported. Metronidazole is not active
against most strains of Actinomyces and has no activity against
aerobic organisms. Clindamycin, however, has the advantage of
activity against Staphylococcus aureus. Streptococcus pyogenes. Streptococcus pneumoniae, and Streptococcus viridans.
Chloramphenicol is active not only against anaerobes but also
againsi aerobes (except Pseudomonas aeruginosa), spirochetes,
rickettsia, chlamydia, and mycoplasma.
Pharmacokinetics
Clindamycin may be given by oral, intramuscular, or intravenous routes. The dose is 300 to 900 mg every 6 to 8 hours with
peak serum concentrations at one hour of 3.6 to 11 pg/mL.
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Clindamycin penetrates most tissues, except for the cerebrospinal fluid. Of special interest is ils higher concentration wilhin
polymorphonuclear leukocytes and macrophages.
Metronidazole can be given via oral or intravenous routes. In
fact, serum concentrations for oral and intravenous routes are
equivalent with peak levels, al one hour, being approximately
25 pg/mL after administering 7.5 mg/kg. The usual dosing interval is 6 to 8 hours; however, because of metronidazole's long
half-life (8 hours), some investigators have given this drug as infrequently as once a day. Clinical experience with this dose
schedule is limited. Metronidazole penetrates all tissues well,
including cerebrospinal fluid, brain, and olher abscesses.
Chloramphenicol may be given by oral, intramuscular, or intravenous routes. An unusual observation is that serum concentration with the oral route is higher than with parenteral routes of
administration (45). This is due to incomplete hydrolysis by the
liver ofthe intravenous preparation, chloramphenicol succinate,
wilh resultant serum concentration of only 70% of those obtained after oral administration. Although tolerated well, the intramuscular route of adminisiration is not recommended because of a high relapse rate related to low serum levels due to
poor absorption of the ester from the injection site. Chloramphenicol penetrates mosttissuesachieving cerebrospinal fluid
levels lhat are 30% to 50% of the serum concentration. Like
metronidazole and clindamycin, chloramphenicol is metabolized primarily in the liver; thus, in renal failure, dose alterations
are not needed.
Efficacy in the intensive care unit
Clindamycin may be u.sed for infections outside ofthe central
nervous system where Bacteroides fragilis or other penicillinresistant anaerobic bacteria are suspected. Thus, in intraabdominal sepsis and in anaerobic pleural-pulmonary infection, clindamycin, when combined with an aminoglycoside, has become a
first-line therapy. Previous recommendations for anaerobic pulmonary infections have emphasized penicillin; however, a recent study of putrid lung abscess showed clindamycin lo be
more effective lhan penicillin (46).
Anolher area for clindamycin is in the patient with penicillin
allergy who has a methicillin-sensitive Staphylococcus aureus
ora penicillin-sensitive anaerobic infection such as Clostridium
peiflingens.
Metronidazole can be used in intraabdominal sepsis but must
be combined with an agent effeciive against aerobic gram-negative organisms. In such cases, metronidazole is considerably
more cost-effective than clindamycin. In addition, metronidazole is active against Bacteroides fragilis resistant to clindamycin. In pulmonary infections, metronidazole has been associated with an unacceptable failure rate and must always be combined with a second agent, such as a beta-lactam antibiotic active against aerobes found in the oral cavity.
Metronidazole has become a preferred agent in the treatment
of anaerobic central nervous system infections. In anaerobic infections at any site, clinical failure may occur with metronidazole if Actinomyces are encountered.
Chloramphenicol is seldom used for anaerobic infection in
view of the efficacy and safety profiles of clindamycin and met-
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ronidazole. Intensive care use of chloramphenicol is limited to
unusual infections such as salmonella resistant to ampicillin and
sulfamethoxazole/trimethoprim, penicillin-allergic patients with
pneumococcal or meningococcal meningitis, and rickettsial infections such as Rocky Mountain spotted fever and typhus.
Adverse effects
Side effects of clindamycin include rash, fever, anaphylaxis,
hepatotoxicity, reversible neutropenia, thrombocytopenia, and
leukopenia. Gastrointestinal side effects are the most common,
with up to 20%) of patients having diarrhea and 0.01% to 10%
developing pseudomembranous enterocolitis. In the case of
clindamycin-associated enterocolitis, diagnosis should be made
by demonstrating toxin in the stool. If su.spected, the offending
antimicrobial should be discontinued and vancomycin administered orally in doses of 125 to 500 mg every 6 hours.
Metronidazole is generally well tolerated with few serious
side effects. Neurologic side effects have included seizures,
ataxia, neuropathy, and encephalopathy. Other reactions have
included potentiation of Coumadin, metallic taste, gastrointestinal disturbances, urticaria, and reversible neutropenia.
The major toxicity of chloramphenicol that has limited its
clinical use has been concem over the idiosyncratic reaction of
aplastic anemia which occurs only in one of 25,000 to 40,000
patients who receive the drug. Other side effects include reversible dose-related bone marrow depression manifested by reticulocytopenia, anemia, leukopenia, and thrombocytopenia, as
well as optic neuritis, gray baby syndrome, hypersensitivity reaction, gastrointestinal symptoms, rash, and drug fever.

Sulfamethoxazole/Trimethoprim
Sulfamethoxazole/trimethoprim is used with increasing frequency in the intensive care unit. The main indications have
been Pneumocystis carinii, nocardia infection, gram-negative
infection where Pseudomonas aeruginosa is not suspected, and
methicillin-resistant Staphylococcus aureus (47), The drug may
be given in doses of 7 to 20 mg/kg/day of trimethoprim in two to
four divided doses. In the case of Pneumocystis carinii pneumonia, the higher dosage recommendation should be given. The
drug penetrates most body tissues including the central nervous
system. Side effects include nausea, vomiting, diarrhea, hypersensitivity reactions, leukopenia, thrombocytopenia, and renal
dysfunction. In addition, sulfamethoxazole/trimethoprim may
interfere with some of the melhods to determine serum creatinine, giving a fafse elevation.

Erythromycin
Erythromycin has also increased in usage in the intensive care
unit, especially for the treatment of Legionella species. Mycoplasma pneumoniae, diphtheria, pertussis, chlamydia, and Campylobacter infections. When given intravenously, the dose is
500 to 1,000 mg every 6 hours. Side effects include phlebitis,
nausea, vomiting, diarrhea, pseudomembranous enterocolitis,
sensorineural hearing loss, fever, rash, eosinophilia, and hepatotoxicity.
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Quinolones
The quinolone group of antimicrobial agents appears to be
highly effective against the enterobacteriareae. The available
quinolones, ciprofloxacin, ofloxacin, and norfloxacin, have
poor activity against streptococci and anaerobes. Ciprofloxacin
has marginal activity against Staphylococcus aureus and Pseudtmtonas aeruginosa with the emergence of resistance to these
pathogens becoming commonplace.
To date, ciprofloxacin is the only available parenteral quinolone. The dose recommended is 400 mg intravenously every
12 hours. It is important to keep in mind the problem of drug interactions. In the intensive care unit the major drug of concern
would be theophylline which will have decreased excretion
in the presence of ciprofloxacin therapy. Theophylline levels
should be monitored and dose adjustments made accordingly to
avoid theophylline toxicity.
The most important role for parenteral ciprofloxacin in the intensive care unit will be for Pseudomonas aeruginosa and other
gram-negative organisms resistant to beta-lactams and/or aminoglycosides. In addition, the quinolones have good in vitro
activity against atypical pneumonia pathogens including Legionella pneumophila and Chlamydia pneumoniae.

Antifungal Therapy
Antifungal therapy in the intensive care unit is usually limited
to parenteral agents, specifically amphotericin B which is used
in the therapy of candidiasis, cryptococcosis, histoplasmosis,
blastomycosis, coccidioidomycosis, aspergillosis, mucormycosis, and vLsceral sporotrichosis. Therapy should be initiated with
a I mg test dose over 1 to 2 hours to assess the patient's febrile
and cardiopulmonary response. The dose may then be increased
to 0.3 mg/kg/day which should be given over 4 to 6 hours. Over
three to five days, the dose may be increased to 0.6 mg/kg/day.
Infusion reactions may be reduced by administration of benadryl. antipyretics, heparin (1.000 units), and hydrocortisone (50
to 100 mg). Side effects that may necessitate reduction or temporary discontinuance of therapy include azotemia, anaphylaxis, fever, rigors, hypokalemia, anemia, thrombocytopenia,
and leukopenia. 5-Flucytosine should be combined with amphotericin in treating cryptococcal disease, and serum levels
should be carefully monitored to avoid bone marrow suppression.
The antifungalfluconazoleis available in parenteral and oral
forms. In the intensive care unit this agent could be used as a second-line therapy in cryptococcal meningitis for the patient who
cannot be treated with amphotericin or as maintenance therapy
after a succes.sful induction with amphotericin. The use of fluconazole in disseminated candidiasis has not been sufficiently
studied to recommend its use over amphotericin at this time.

Acyclovir
Acyclovir is the antiviral agent of greatest value to the intensive care patient. This purine nucleoside analogue can be used
for herpes simplex encephalitis, disseminated herpes simplex
infection, localized varicella zoster in immunocompromised patients, and dis.seminaled varicella infection. The dose of acy-
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clovir is 5 to 10 mg/kg every 8 hours, with the higher dose being
used for herpes encephalitis, disseminated or localized varicella
zoster, and disseminated herpes simplex infection. The toxicity
ofacyclovir is minimal with less than I % of patients developing
serious side effects. Reported side effects include headache,
nausea, rash, hypotension, lethargy, obtundation, seizures, or
coma. Renal dysfunction may occur ifthe patient is dehydrated,
and crystalluria is a concem as well. Thus, adequate hydration is
critical when administering acyclovir.
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